CAJ | 학술논문

目的探讨DNA修复酶O6-甲基鸟嘌呤DNA甲基转移酶(MGMT)及抑癌基因p53在非小细胞肺癌(NSCLC)中的表达及其与预后的关系. 方法采用免疫组织化学SP法检测110例NSCLC患者及20例肺部良性病变患者术后肺组织中MGMT及p53的表达,并观察110例NSCLC根治术后患者的生存期. 结果 110例NSCLC患者及20例肺良性病变患者组织中MGMT蛋白阳性表达率分别为41.8%(46/110)和80%(16/20),p.53蛋白的阳性表达率分别为56.4%(62/110)和0%(0/20)例,MGMT蛋白表达与淋巴结转移及吸烟史相关(x2值为12.107和6.512,均P<0.05),p53蛋白表达亦与淋巴结转移及吸烟史相关(X2值为6.330和7.909,均P<0.05),MGMT和p53蛋白表达呈负相关(Rs=-0.592,P<0.05).110例患者的5年生存率为10.9%(12/110),中位生存期为(30.4±0.6)个月;46例MGMT表达阳性的患者5年生存率为0%(0/110),中位生存期为(25.9±0.4)个月,均低于64例MGMT表达阴性患者的5年生存率(18.8%,12/64)和中位生存期[(32.4±0.7)个月],差异有统计学意义(x2=23.569,P<0.05).62例053表达阳性患者的5年生存率为4.8%(3/62),中位生存期为(30.4±1.2)个月,均低于48例p53表达阴性患者的5年生存率(18.8%,9/48)和中位生存期[(30.5±1.1)个月],差异有统计学意义(x2=5.521,P<0.05). 结论 NSCLC患者体内MGMT表达缺失可能与突变型p53的表达水平有关,且与肺癌的发生、发展及预后相关.
목적 탐토DNA수복매O6-갑기조표령DNA갑기전이매(MGMT)급억암기인p53재비소세포폐암(NSCLC)중적표체급기여예후적관계. 방법 채용면역조직화학SP법검측110례NSCLC환자급20례폐부량성병변환자술후폐조직중MGMT급p53적표체,병관찰110례NSCLC근치술후환자적생존기. 결과 110례NSCLC환자급20례폐량성병변환자조직중MGMT단백양성표체솔분별위41.8%(46/110)화80%(16/20),p.53단백적양성표체솔분별위56.4%(62/110)화0%(0/20)례,MGMT단백표체여림파결전이급흡연사상관(x2치위12.107화6.512,균P<0.05),p53단백표체역여림파결전이급흡연사상관(X2치위6.330화7.909,균P<0.05),MGMT화p53단백표체정부상관(Rs=-0.592,P<0.05).110례환자적5년생존솔위10.9%(12/110),중위생존기위(30.4±0.6)개월;46례MGMT표체양성적환자5년생존솔위0%(0/110),중위생존기위(25.9±0.4)개월,균저우64례MGMT표체음성환자적5년생존솔(18.8%,12/64)화중위생존기[(32.4±0.7)개월],차이유통계학의의(x2=23.569,P<0.05).62례053표체양성환자적5년생존솔위4.8%(3/62),중위생존기위(30.4±1.2)개월,균저우48례p53표체음성환자적5년생존솔(18.8%,9/48)화중위생존기[(30.5±1.1)개월],차이유통계학의의(x2=5.521,P<0.05). 결론 NSCLC환자체내MGMT표체결실가능여돌변형p53적표체수평유관,차여폐암적발생、발전급예후상관.
Objective To investigate the expression and role of O~6-methylguanine DNA methyltransferas(MGMT) and p53 in non-small cell lung cancer(NSCLc)and the association with prognosis. Methods Immunohistochemical method was used to investigate the expression of MGMT and p53 in NSCLC specimens from 110 cases and in 20 cages of benign lung diseases as the control.The association of their expression with the prognosis of the 110 patients was evaluated. Results The positive expression of MGMT in NSCLC and benign lung diseases was 41.8%(46/110)and 80%(16/20)(x2=9.89,P<0.05),respectively.The positive expression of p53 in NSCLC and benign lung diseases were 56.4%(62/110)and 0%(0/20)(x2=21.551,P<0.05),respectively.There was a significant association between expression of MGMT with smoking,and lymph node metastasis (x2=12.107,P<0.05;x2=6.512P<0.05).There was also a significant association between expression of p53 with smoking and lymph node metastasis(x2=6.330,P<0.05;x2=7.909,P<0.05).A negative correlation was observed between the expression of MGMT and that of p53 protein in NSCLC(R_S=-0.592,P<0.05).The 5-year survival rate and median survival time of 110 cages was 10.9%(12/110),and(30.4±0.6)months.In 46 cases with positive expression of MGMT the 5-year survival rate was 0%(0/110)and median survival was(25.9±0.4)months,which were lower than those in the 64 patients with negative expression of MGMT [18.8%(12/64),(32.4 ±0.7)months],Log rank test x2=23.569,P<0.05.in the 62 patients with positive expression of p53.the 5-year survival rate and modian survival were 4.8%(3/62)and(30.4±1.2)months,which were lower than those in the 48 cases with negative expression of p53[18.8%(9/48),(30. 5± 1.1 ) months], Log rank test X2 =5. 521, P <0. 05. Conclusion The loss of expression of MGMT may lead to activation of the wild-type p53. They may participate in lung carcinomatosis, and may predict prognosis in patients with NSCLC.